Friday, September 4, 2026

Aspen Group Stock Over 5% Up So Far Today

ViaNews Editorial Team

November 25, 2020

Aspen Group Stock Over 5% Up So Far Today

Shares of Aspen Group rose 5.99% to $12.20 at 14:13 EST on Wednesday, following yesterday's downward trend. The Nasdaq Stock Market is rising 0.04% to $11,895.20, after two sequential sessions in a row of losses, on what at the moment seems, a somewhat positive trend exchanging session today.

Aspen Group's last close was $10.49, 7.87% under its 52-week high of $13.16.

The company's growth estimates for the present quarter is a negative 33.3% and positive 75% for the next.

Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 53.87M for the twelve trailing months.

Aspen Group's stock is valued at $12.20 at 14:13 EST, under its 52-week high of $13.16 and way higher than its 52-week low of $4.65.

Aspen Group's value is way above its 50-day moving average of $11.03 and way higher than its 200-day moving average of $9.95.

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com